Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | VHL T133fs |
Therapy | Belzutifan |
Indication/Tumor Type | clear cell renal cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
VHL T133fs | clear cell renal cell carcinoma | predicted - sensitive | Belzutifan | Case Reports/Case Series | Actionable | In a clinical case study, Welireg (belzutifan) treatment resulted in a durable response lasting at least 1.5 years in a heavily-pretreated clear cell renal cell carcinoma patient harboring VHL T133fs (PMID: 38344974). | 38344974 |
PubMed Id | Reference Title | Details |
---|---|---|
(38344974) | Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation. | Full reference... |